Spectral properties and crystal structure of bis(μ-thiocyanato-N,S)bis-(thiocyanato-N)tetrakis(5,7-dimethyl[1,2,4]triazolo[1,5-α]pyrimidine-N3)dicopper(II) and of tetrakis(5,7-dimethyl[1,2,4]triazolo[1,5-α]pyrimidine-N3)platinum(II) hexa(thiocyanato-S)platinate(IV)

Mono- and dinuclear platinum(II) compounds with 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine. Structure, cytotoxic activity and reaction with 5'-GMP

Mono- and dinuclear platinum(II) coordination compounds of formula cis-[PtCl(2)(NH(3))(dmtp)], 1, cis-[PtCl(2)(dmtp)(2)], 2 and {H(+)[C(28)H(32)Cl(2)N(16)Pt(2)](2+)(NO(3))(3)(H(2)O)(6)}, 3, in which dmtp is 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine have been synthesized and characterized by infrared and by (1)H, (13)C, (195)Pt NMR spectroscopy. The coordination units of the cationic species of formula [Pt(2)(mu-dmtp)(2)Cl(2)(dmtp)(2)](2+) are built up by two platinum atoms in a square-planar environment. Two sites are occupied by two 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine (dmtp) bridging ligands which are linked to both metal atoms through their nitrogen atoms in positions 3 and 4. The other two positions are occupied by one monodentate 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine (dmtp) molecule and a coordinated chloride. This compound is the first in which the same triazolopyrimidine ligand (dmtp) coordinates to a metal ion in two different ways, i.e. bridging bidentate and non-bridging monodentate. In addition, the interaction of compounds 1 and 2 with 5'-GMP was investigated in solution by (1)H NMR spectroscopy. The cytotoxicity of all the new platinum(II) compounds were studied by using two different cell lines: T47D (breast cancer) and HCV29T (bladder cancer).

Tricopper(ii) complexes of unsymmetrical macrocycles incorporating phenol and pyridine moieties: the development of two stepwise routes

Two stepwise approaches to preparing large unsymmetrical macrocycles incorporating diethylenetriamine lateral units are described: the first utilises protecting group chemistry, whereas the second exploits irreversible amide bond formation in the presence of an excess of the amine. In the first approach condensation of two equivalents of N-acetyldiethylenetriamine 1 with 2,6-diformyl-4-methylphenol, followed by a sodium borohydride reduction of the newly formed imine bonds and acidic removal of the protecting groups, yields a phenol-containing "two-armed" precursor as an HCl salt 2. Using the second approach the new pyridine-containing "two-armed" precursor , is prepared from 2,6-dimethylpyridinedicarboxylate and an excess of diethylenetriamine. These two "two-armed" di-primary amine precursors, 2 (after reaction with KOH) and 3, can be condensed with the dicarbonyl head units of choice. The lead templated condensation of 2 with 2,6-diacetylpyridine results in the formation of the macrocyclic dilead(II) complex {[Pb(II)(2)(L1)(Cl)](ClO(4))(2)}(infinity) 4. Transmetallation of 4 with three equivalents of copper(II) perchlorate produces Cu(II)(3)(L1)(OH)(ClO(4))(4) 5. Condensation of 3 with 2,6-diacetylpyridine or 2,6-diformylpyridine in the presence of barium(ii) ions results in the macrocyclic complexes [Ba(II)(H(2)L2)](ClO(4))(2) 6 and [Ba(II)(H(2)L3)](ClO(4))(2) 7, respectively. Copper(II) acetate templates the formation of the crystallographically characterised unsymmetrical macrocyclic complex [Cu(II)(3)(L4)(OH)(NCS)(2)].EtOH, 8.EtOH, from 3, 2,6-diformyl-4-methylphenol and NaNCS.

Multinuclear NMR spectroscopy and antitumor activity of novel platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5- a ]pyrimidines

Novel platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines have been synthesized and characterized by infrared and multinuclear magnetic resonance spectroscopic techniques (1H, 13C, 15N, 195Pt). The complexes are of two types: [PtCl2(L)2] and [PtCl2(NH3)(L)], where L=5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine (dptp) and 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine (dbtp). Significant 15N NMR upfield shifts (92-95 ppm) were observed for N(3) atom indicating this nitrogen atom as a coordination site. The molecular structure suggest that Pt(II) ion has the square planar geometry with N(3) bonded 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines, N-bonded second ligand (NH3 for cis-[PtCl2(NH3)(L)] or, respectively, 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines for cis-[PtCl2L2]) and two cis chloride anions. The antiproliferative activity in vitro of complexes (1-4) have been tested against the cells of four human cell lines: SW707 rectal adenocarcinoma, A549 non-small cell lung carcinoma, T47D breast cancer and HCV29T bladder cancer. The results indicate a moderate antiproliferative activity of (4) against the cells of rectal, breast and bladder cancer and a marked and selective cytotoxic effect of (1-3) against the cells of all studied human cancer lines.